Wayfinder Biosciences

Wayfinder Biosciences is an early-stage biotech developing RNA-targeting small molecules to address undruggable disease targets. The company's platform integrates RNA-based sensors and AI/ML to discover compounds that bind to specific mRNA structures, halting protein production before it begins. Its initial pipeline focuses on high-value targets in oncology and neurodegeneration. As a private, pre-revenue company, Wayfinder is building its foundational platform and asset pipeline while seeking partnerships to expand into broader therapeutic areas.

Proprietary platform combining unique RNA-based sensors and a data generation engine with AI/ML screening to discover potent, selective, and biologically active small molecules that target specific structured pockets in mRNA.

Wayfinder competes in the emerging RNA-targeting small molecule space with companies like Arrakis Therapeutics, Skyhawk Therapeutics, and Expansion Therapeutics, as well as large pharma initiatives. Differentiation hinges on the specifics of its sensor technology and AI/ML integration for predicting selective, functional compounds.